Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease.
about
Mycophenolate mofetil (MMF) for the treatment of connective tissue disease-associated interstitial lung disease (ILD)My approach to the treatment of sclerodermaPharmacotherapy of systemic sclerosisImmunotherapy of systemic sclerosisCurrent perspectives on the immunopathogenesis of systemic sclerosisTherapeutic Approach to Adult Fibrotic Lung DiseasesRecent Treatments of Interstitial Lung Disease with Systemic SclerosisTreatment of rheumatoid arthritis-associated interstitial lung disease: a perspective reviewManagement of Systemic-Sclerosis-Associated Interstitial Lung DiseaseReview: Hematopoietic Stem Cell Transplantation for Scleroderma: Effective Immunomodulatory Therapy for Patients With Pulmonary InvolvementMolecular targets for therapy in systemic sclerosisAn Update on the Treatment of the Cutaneous Manifestations of Systemic Sclerosis: The Dermatologist's Point of View.Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle studyPredicting treatment outcomes and responder subsets in scleroderma-related interstitial lung disease.Scleroderma lung diseaseSystemic Sclerosis-Associated Interstitial Lung Disease: Lessons from Clinical Trials, Outcome Measures, and Future Study Design.Twenty-two points to consider for clinical trials in systemic sclerosis, based on EULAR standards.Lung involvement in systemic sclerosis.Inflammatory leukocyte phenotypes correlate with disease progression in idiopathic pulmonary fibrosis.Long term effects of cyclophosphamide treatment on lung function and survival in scleroderma patients with interstitial lung diseaseReview: interstitial lung disease associated with systemic sclerosis and idiopathic pulmonary fibrosis: how similar and distinct?Treatment with imatinib results in reduced IL-4-producing T cells, but increased CD4(+) T cells in the broncho-alveolar lavage of patients with systemic sclerosis.Interstitial Lung Disease in Children Older Than 2 Years.Effect and safety of mycophenolate mofetil or sodium in systemic sclerosis-associated interstitial lung disease: a meta-analysisOld medications and new targeted therapies in systemic sclerosis.Correlation of cough with disease activity and treatment with cyclophosphamide in scleroderma interstitial lung disease: findings from the Scleroderma Lung Study.Connective Tissue Disease-associated Interstitial Lung Disease: A review.Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis-associated interstitial lung disease trials.Diagnosis and treatment of connective tissue disease-associated interstitial lung disease.Connective Tissue Disease-associated Interstitial Lung Diseases (CTD-ILD) - Report from OMERACT CTD-ILD Working Group.Outcomes in systemic sclerosis-related lung disease after lung transplantation.Trial design: how must we move ahead?Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease.Cyclophosphamide versus mycophenolate mofetil in scleroderma interstitial lung disease (SSc-ILD) as induction therapy: a single-centre, retrospective analysisUpdate in diffuse parenchymal lung disease 2007.Treatment of systemic sclerosis: potential role for stem cell transplantation.Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studiesTherapies for interstitial lung disease: past, present and future.Treatment of scleroderma-interstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic high-resolution CT scan than placebo: findings from the scleroderma lung study.
P2860
Q24203019-776E7DC0-110F-425A-9EAA-D51E5E1A6613Q24618843-895C1F09-FDE0-4A00-8E98-CA0E4CD7624AQ24629481-B6C68D0B-B7E4-43D2-BB32-D7EE5B3F3E81Q24634395-90B1F95E-16D0-4FAE-AAA9-2AA14FBD9D31Q26741264-B33B386D-A785-4728-A3F8-9FBCDEB5C6D5Q26741569-A28951A0-0255-4CB3-92A5-D7D01A825574Q26773161-02D57168-9EFC-4D9B-9520-5E8A71E43582Q26775753-3C5DD47C-FFCE-4DD2-B0C3-BE8D745817FDQ26799573-7633E4C6-4D19-453F-BEAB-920E2C01DE66Q28080076-600D6F0E-823C-4B5B-9BAE-5933CBAC7812Q28484123-BD623B05-7CC3-4601-8826-302FFEB251A7Q30465733-A11A9888-3E63-404E-9C84-95204DCC7BFEQ33434238-1C08A92D-E8DA-4D78-AF3A-D90AA3AD06E2Q33588875-D8FEA467-9A35-4443-8D17-249638A9D4A3Q33891119-8CD247E0-CD8E-40C6-A842-B55B6E927655Q33919119-5B063AB4-3C4B-49B0-99DC-33E378A65489Q34027197-3CBA9A49-2FB4-408E-B45A-C0C4B9AAF32DQ34727670-DBDEB507-CC14-4496-85FA-835132068270Q34732817-630C5F58-7941-4319-AB0E-5BC53898A08DQ34857355-411B52E0-583E-4CF8-9EFF-37B072311F3CQ34921541-67BFE01A-CB70-4F03-9A67-59439B5CA4C2Q35121494-8E135088-95DB-432D-9353-9BC7287DFA95Q35566387-31524F88-4B41-405A-8618-BF2F726E7921Q35716057-0296348E-E8C0-4220-82EC-C06E0C2B6AB0Q35977704-FC77E950-C151-4DE0-B20C-97952808A6AFQ36154430-039246CC-41ED-4D62-AFF5-44ADE49C1FDCQ36212638-106A423A-2B8E-498E-A0DE-48E7E46FC52AQ36363696-F66B06DB-3B1C-4327-9987-4E0B7DF8160FQ36477472-B3D37547-541E-46D8-AAA7-7C8F9698FC0FQ36664408-809B457E-E3DC-40F7-A44E-D1088C306A30Q36733756-AC40818C-FCCB-408E-994E-61DCFA90D9ECQ36739951-42CECD72-CA35-482E-9C6C-EDB3207155A1Q36869407-152315A2-E4A6-410D-ACEB-B699F844DCCEQ36913821-BE981E43-FA08-4335-8890-7EAC1143FC01Q36960060-A0A4DE18-BFCC-4F19-926B-AB0282AB0AA3Q37100706-EA16C5D4-1A78-4CF7-BA40-A27634A4955DQ37194001-D617C9D6-5E3B-461E-AFD2-2AC4B60558D8Q37304301-FC9429CC-3087-4A42-9420-2338DDAB00B2Q37362642-FDE5A020-A3E8-4FB7-8E2C-8705A1517A5DQ37412005-258B2CA8-B15D-4C73-B29D-0F98D718701C
P2860
Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Effects of 1-year treatment wi ...... s in scleroderma lung disease.
@ast
Effects of 1-year treatment wi ...... s in scleroderma lung disease.
@en
type
label
Effects of 1-year treatment wi ...... s in scleroderma lung disease.
@ast
Effects of 1-year treatment wi ...... s in scleroderma lung disease.
@en
prefLabel
Effects of 1-year treatment wi ...... s in scleroderma lung disease.
@ast
Effects of 1-year treatment wi ...... s in scleroderma lung disease.
@en
P2093
P2860
P50
P1476
Effects of 1-year treatment wi ...... rs in scleroderma lung disease
@en
P2093
Arthur Theodore
Barbara White
Barri Fessler
Charles Read
Daniel E Furst
David J Riley
Dinesh Khanna
Donald P Tashkin
Ed Parsley
Edgar Arriola
P2860
P304
P356
10.1164/RCCM.200702-326OC
P407
P577
2007-08-23T00:00:00Z